Judgements and settlements are starting in Oklahoma against various pharmaceutical companies for their alleged roles in that state’s opioid crisis. Who would be the beneficiaries of these funds?
Thomas R. Kosten, MD
This overview addresses two medications for analgesia of chronic benign pain, both of which have substance abuse risks themselves.
The cannabinoids (particularly CBD) have been hailed as non-addictive solutions to using escalating doses of opioids for chronic pain. More in this research update.
An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.
What's the optimal strategy toward recovery from opioid use disorder? Which treatment for nicotine addiction has the most favorable adverse-effect profile?
A clinical collection on addiction treatment, ADHD and SUDs, important drug indications, vaping, cannabis use, benzodiazepines, the perils of self-medicating and other topics relevant to practicing psychiatrists.
Significant progress has been made in containing the opioid epidemic, but new threats loom. Thomas Kosten, MD, an addiction psychiatrist, takes a brief look.
The Chair of a Special Report on substance abuse disorders describes the highlights of 6 articles in the series.
There are no FDA-approved pharmacotherapies for cocaine use disorder. Here: a review of the off-label use of promising medications for this addiction.